Evidence map›Paper›PMID 41140301›Full record

ArticleAdvances in radiation oncology2025

A Precise Reirradiation Supporting Tool Initiative (PRISTIN) for Prescribing Absorbed Dose and Number of Fractions in Reirradiation.

Mayu Hagiwara, Ryusuke Suzuki, Seishin Takao, Rumiko Kinoshita, Shizusa Yamazaki, Keiji Nakazato, Hideki Kojima, Takayuki Hashimoto, Keiji Kobashi, Yasuhiro Onodera and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mayu HagiwaraGraduate School of Biomedical Science and Engineering, Hokkaido University, Sapporo, Japan.
Ryusuke SuzukiGraduate School of Biomedical Science and Engineering, Hokkaido University, Sapporo, Japan.
Seishin TakaoDepartment of Medical Physics, Hokkaido University Hospital, Sapporo, Japan.
Rumiko KinoshitaDepartment of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan.
Shizusa YamazakiGraduate School of Biomedical Science and Engineering, Hokkaido University, Sapporo, Japan.
Keiji NakazatoDepartment of Medical Physics, Hokkaido University Hospital, Sapporo, Japan.
Hideki KojimaDepartment of Radiation Oncology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
Takayuki HashimotoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Keiji KobashiGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Yasuhiro OnoderaGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hisanori FukunagaDepartment of Biomedical Science and Engineering, Faculty of Health Sciences, Hokkaido University, Sapporo, Japan.
Hidefumi AoyamaDepartment of Radiation Oncology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Michael F GensheimerDepartment of Radiation Oncology, School of Medicine, Stanford University, Stanford, CA, United States.
Masahiro MizutaThe Institute of Statistical Mathematics, Tachikawa, Japan.
Hiroki ShiratoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aims to develop a supporting tool to calculate the most appropriate prescribing absorbed dose and number of fractions for precise reirradiation. Methods and Materials: After deformable image registration of the initial computed tomography to the computed tomography at reirradiation, an initial biological effective dose (BED) taking into account the recovery from the initial irradiation is calculated voxel-by-voxel for each organ at risk (OAR). Using a commercial radiation therapy planning system, the clinical target volume for reirradiation (CTV2) is made. Keeping the BED Results: In scenario 1, giving 57 Gy in 22 fractions (57 Gy/22 Fr) to the CTV2 at the right hilum, the maximum CBED Conclusions: The tool was suggested to be useful to find the most appropriate prescribing absorbed dose to the target as well as the number of fractions for precise reirradiation.

Identifiers

PMID41140301
PMCPMC12547464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.